Research & Innovation
From The Report: Mexico 2017
View in Online Reader

Mexico has long recognised the importance of research and innovation to the development of a strong and sustainable economy. To date, however, the goal of boosting research and development (R&D) spending to 1% of GDP has remained somewhat distant, with public spending across a variety of programmes having an only limited effect on encouraging the development of new technologies and innovative companies. Facing lower budgets in 2017, the government will be more selective in the projects it sponsors and is looking to incentivise further private investment in R&D. Improvements to the intellectual property framework are set to give foreigner investors additional confidence in this area. The target of spending 1% of GDP on R&D by 2018 looks out of reach; nevertheless, the belt-tightening process is likely to have positive effects on the efficiency of public R&D spending in the future. The increased focus on advanced-stage projects and closer monitoring of outcomes should lead to more demonstrable results. This chapter contains an interview with Guillermo Echeverría Miller, CEO, Vuhl.

Articles from this Chapter

Overview

Testing a new path: Further private sector involvement and a more efficient use of public funds promote new developments
OBG
plus

Mexico has long recognised the importance of research and innovation to the development of a strong and sustainable economy. To date, however, the goal of boosting research and development (R&D) spending to 1% of GDP has remained somewhat distant, with public spending across a variety of programmes having an only limited effect on encouraging the development of new technologies and innovative companies. Facing lower budgets in 2017, the government will be more selective in the projects it sponsors…

Analysis

Big business: Pharmaceutical companies capitalise on market conditions
OBG
plus

The Mexican pharmaceutical industry has potential for the deployment of research and development (R&D) capital. Since 2010 the strategy of the Federal Commission for the Protection from Sanitary Risk (Comisión Federal para la Protección contra Riesgos Sanitarios, Cofepris), the regulatory body governing the sector, has enabled faster licensing of new products and allowed Mexico to become one of the most developed markets for generic drugs in the world. “Cofepris has implemented new reforms,…

Interview

Commit and collaborate: Guillermo Echeverría Miller, CEO, Vuhl, on how research and development (R&D) can help the manufacturing sector
OBG
plus

Interview:Guillermo Echeverría Miller How can Mexico’s burgeoning manufacturing sector benefit from a commitment to R&D? GUILLERMO ECHEVERRÍA MILLER: R&D in Mexico currently represents approximately 0.5% of GDP, which reveals our limited tendency towards research activities. However, the government is committed to increasing this budget to 1% by 2018 with institutions such as The National Council for Science and Technology (Consejo Nacional de Ciencia y Tecnología, CONACYT) and…